Researchers Urge Caution Using IDAA1c to Screen Youth for Diabetes Remission

Baylor College of Medicine

A Baylor College of Medicine-led team is raising awareness about applying the widely used values of insulin dose-adjusted hemoglobin A1c (IDAA1c) when screening for partial type 1 diabetes remission in youth with overweight or obesity. The study appeared in Diabetes Care .

"After a person is diagnosed with type 1 diabetes and receives insulin treatment, some still produce a meaningful amount of their own insulin for a time. This temporary stage, known as partial remission or the 'honeymoon phase,' is associated with better blood sugar control, fewer episodes of low blood sugar and potentially a lower risk of long-term diabetes complications," said corresponding author Dr. Maria J. Redondo , professor of pediatrics – diabetes and endocrinology at Baylor and Texas Children's Hospital. "Because of these benefits, researchers and clinicians are interested in accurately identifying who is in this phase."

The most accurate way to measure remaining insulin production is through a laboratory test called stimulated C-peptide test. However, this test is time-consuming and not practical for routine clinical use. Instead, many doctors and researchers use IDAA1c, a calculation based on two readily available measurements: hemoglobin A1c (a marker of average blood sugar levels) and daily insulin dose. An IDAA1c value of nine or less has traditionally been used to indicate partial remission.

"However, the IDAA1c values were determined in a primarily Northern European population, and have not been validated in U.S. youth, of which a large proportion is overweight or obese," said first author Dr. Michael L. Ferm, who was pediatric endocrinology fellow working in the Redondo lab during this project. "Overweight and obesity increase insulin resistance and insulin requirements so we hypothesized that IDAA1c would not reflect accurate estimates of insulin values in participants with overweight or obesity."

To evaluate how well the current IDAA1c standard works in U.S. children and adolescents, the team analyzed data from 422 participants in the SEARCH for Diabetes in Youth Study who were within one year of diagnosis. They compared IDAA1c results with stimulated C-peptide levels, which served as the reference standard for identifying partial remission.

"We found that using the standard cutoff of nine or less correctly identified only about 61% of youth who were in partial remission, while correctly identifying about 79% of those who were not. Therefore, many young people who still had meaningful insulin production were missed by the IDAA1c test," Redondo said.

"Importantly, in the group including children and adolescents with overweight or obesity, the standard IDAA1c threshold identified only 45% of participants who were in partial remission according to their C-peptide results," Ferm said. "This result indicates that the standard IDAA1c would miss more than half of the children who were still producing a meaningful amount of insulin. The test may incorrectly suggest that partial remission has ended."

The investigators explored whether a higher threshold for youth with overweight or obesity would improve accuracy. Raising the cutoff to 11.6 from nine increased the ability to detect partial remission, but it also increased the number of false-positive results. This tradeoff meant overall performance remained less than ideal and would need to be reevaluated.

"Our study concludes that IDAA1c should be used cautiously when evaluating individual patients, especially those with overweight or obesity," Redondo said. "There is a need for better, more reliable methods to define and measure partial remission in type 1 diabetes."

"This project began as part of Dr. Ferm's training during his pediatric endocrinology fellowship," said Redondo. "Fellows identify a mentor for their research project. Dr. Ferm brought me the idea that IDAA1c might not accurately reflect insulin secretion in children with type 1 diabetes and overweight or obesity. We developed the project together, and he took the lead. That balance – fellows leading their projects with close guidance and collaboration from faculty mentors – is central to our fellowship program's approach to research training. The result of this wonderful experience, now published in a premier journal in our field, offers a new perspective on the topic and has direct implications for people with diabetes."

Other contributors to this work include Xiaofan Huang, Charles G. Minard, Daniel J. DeSalvo, Amy S. Shah, Catherine Pihoker and Anna C. Bellatorre. The authors are affiliated with Baylor College of Medicine, Texas Children's Hospital, Cincinnati Children's Hospital Medical Center and University of Cincinnati, University of Washington in Seattle and University of Colorado Anschutz in Aurora.

For a complete list of the sources of support for this project, see the publication.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.